Nicole is a medical doctor with over 20 years of industry experience in clinical development of targeted cancer therapies.
Basel, Switzerland, November 28, 2017 / B3C newswire / -- Today NBE Therapeutics, a biopharmaceutical company developing next-generation antibody drug conjugates (ADCs) carrying highly potent, immune-stimulatory anthracycline toxins, announces the appointment of Dr. Nicole Onetto to its Board of Directors.
Nicole is a medical doctor with over 20 years of industry experience in clinical development of targeted cancer therapies. She has held senior medical positions at Hoechst/Canada, Immunex, Bristol-Myers-Squibb, Gilead, OSI Pharmaceuticals and Zymogenetics. In addition, she served on the Board of Immunogen Inc. for eleven years, one of the pioneers in the ADC field. Most recently Nicole was the Deputy Director and Chief Scientific Officer at the Ontario Institute for Cancer Research. In addition to NBE-Therapeutics, Nicole also serves on the Boards of two public companies, Basilea Pharmaceuticals, Switzerland, and Sierra Oncology, Canada.
Nicole is an internationally recognized leader with a strong track record in the development of oncology drugs. Her work was instrumental in the successful clinical development and world-wide regulatory approvals of several therapeutics, including Taxol® and Tarceva®.
In parallel, Henning Schwanhäusser, co-founder of NBE Therapeutics, has stepped down from NBE’s Board of Directors.
Theo Walthie, Chairman of the Board of NBE-Therapeutics states: “We are excited that Dr. Nicole Onetto, with her extensive experience in clinical development of oncology drugs and ADCs, has joined NBE-Therapeutics’ Board of Directors. This represents a strong validation of our development programs and will help expedite clinical development of our ADCs. I would also like to thank Henning Schwanhäusser for his service on the Board since the inception of NBE. His support and insights were instrumental during the start-up phase of NBE Therapeutics”.
Nicole Onetto added: “I am very intrigued by the quality of NBE-Therapeutics’ ADC discovery and development activities and the potential of NBE-Therapeutics late-stage preclinical ADC assets to become new therapies for hematologic malignancies and solid tumors. NBE-Therapeutics’ technology combines aspects of highly effective tumor targeting characteristic of ADC, but it is also associated with an anti-tumor immunity effect in animal models. This underscores the potential of NBE ADCs to yield durable anti-tumor effects in patients. I am looking forward to working with NBE’s Board and the Executive Team to successfully bring the company’s ADCs through clinical development and to the market for the benefit of cancer patients.”
